ATE522563T1 - Verzweigte polyalkylenglykole - Google Patents
Verzweigte polyalkylenglykoleInfo
- Publication number
- ATE522563T1 ATE522563T1 AT00985846T AT00985846T ATE522563T1 AT E522563 T1 ATE522563 T1 AT E522563T1 AT 00985846 T AT00985846 T AT 00985846T AT 00985846 T AT00985846 T AT 00985846T AT E522563 T1 ATE522563 T1 AT E522563T1
- Authority
- AT
- Austria
- Prior art keywords
- group
- polyalkylene glycols
- branched polyalkylene
- reactivity
- linked
- Prior art date
Links
- 229920001515 polyalkylene glycol Polymers 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000009257 reactivity Effects 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Polymers & Plastics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Polyethers (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP36631299 | 1999-12-24 | ||
| PCT/JP2000/009159 WO2001048052A1 (en) | 1999-12-24 | 2000-12-22 | Branched polyalkylene glycols |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE522563T1 true ATE522563T1 (de) | 2011-09-15 |
Family
ID=18486472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00985846T ATE522563T1 (de) | 1999-12-24 | 2000-12-22 | Verzweigte polyalkylenglykole |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7691367B2 (de) |
| EP (1) | EP1270642B1 (de) |
| JP (1) | JP4593048B2 (de) |
| AT (1) | ATE522563T1 (de) |
| AU (1) | AU2223401A (de) |
| CA (1) | CA2395254C (de) |
| WO (1) | WO2001048052A1 (de) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002043772A2 (en) * | 2000-11-30 | 2002-06-06 | Shearwater Corporation | Water-soluble polymer conjugates of triazine derivatives |
| CA2436623C (en) * | 2001-01-30 | 2011-08-02 | Kyowa Hakko Kogyo Co., Ltd. | Branched polyalkylene glycols |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| US7144978B2 (en) * | 2002-01-15 | 2006-12-05 | Pan Asia Bio Co., Ltd. | Multidrop tree branching functional polyethylene glycol, methods of preparing and using same |
| AU2003303636B2 (en) * | 2002-12-26 | 2010-08-05 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
| GEP20084486B (en) | 2002-12-26 | 2008-09-25 | Mountain View Pharmaceuticals | Polymer conjugates of interferon-beta with enhanced biological potency |
| US7432331B2 (en) | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
| CA2511549A1 (en) * | 2002-12-31 | 2004-07-22 | Medtronic Minimed, Inc. | Hydrophilic cross-linking agents for use in enzymatic sensors |
| WO2004060965A2 (en) * | 2002-12-31 | 2004-07-22 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
| AU2004221824B2 (en) | 2003-03-14 | 2009-08-27 | Ratiopharm Gmbh | Branched water-soluble polymers and their conjugates |
| SG155777A1 (en) | 2003-04-09 | 2009-10-29 | Neose Technologies Inc | Glycopegylation methods and proteins/peptides produced by the methods |
| US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
| US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
| AU2004266969B2 (en) | 2003-08-25 | 2010-02-25 | Taniguchi, Tadatsugu | Interferon-beta composite |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| ES2560657T3 (es) | 2004-01-08 | 2016-02-22 | Ratiopharm Gmbh | Glicosilación con unión en O de péptidos G-CSF |
| WO2006010143A2 (en) | 2004-07-13 | 2006-01-26 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1] |
| PL2586456T3 (pl) | 2004-10-29 | 2016-07-29 | Ratiopharm Gmbh | Remodeling i glikopegilacja czynnika wzrostu fibroblastów (FGF) |
| US9029331B2 (en) | 2005-01-10 | 2015-05-12 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
| EP1871795A4 (de) | 2005-04-08 | 2010-03-31 | Biogenerix Ag | Zusammensetzungen und verfahren zur herstellung von glycosylierungsmutanten eines proteaseresistenten menschlichen wachstumshormons |
| EP1891231A4 (de) | 2005-05-25 | 2011-06-22 | Novo Nordisk As | Glykopegylierter faktor ix |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
| US20080248959A1 (en) | 2006-07-21 | 2008-10-09 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
| JP2010505874A (ja) | 2006-10-03 | 2010-02-25 | ノヴォ ノルディスク アー／エス | ポリペプチドコンジュゲートの精製方法 |
| JP5515224B2 (ja) | 2007-02-28 | 2014-06-11 | 日油株式会社 | 多分岐鎖ポリオキシアルキレン誘導体 |
| BRPI0809670A8 (pt) | 2007-04-03 | 2018-12-18 | Biogenerix Ag | métodos para aumentar a produção de célula tronco, para aumentar o número de granulócitos em um indivíduo, para prevenir, tratar e aliviar a mielossupressão que resulta de uma terapia contra o câncer, para tratar uma condição em um indivíduo, para tratar neutropenia e trombocitopenia em um mamífero, para expandir células tronco hematopoiéticas em cultura, para aumentar a hematopoiese em um indivíduo, para aumentar o número de célulars progenitoras hematopoiéticas em um indivíduo, e para fornecer enxerto estável da medula óssea, e, forma de dosagem oral. |
| MX2009013259A (es) | 2007-06-12 | 2010-01-25 | Novo Nordisk As | Proceso mejorado para la produccion de azucares de nucleotidos. |
| WO2009086656A1 (zh) * | 2007-12-29 | 2009-07-16 | Biosteed Gene Expression Tech. Co., Ltd. | Y型聚乙二醇修饰的g-csf及其制备方法和应用 |
| ES2476690T3 (es) | 2008-02-27 | 2014-07-15 | Novo Nordisk A/S | Moléculas conjugadas del Factor VIII |
| BRPI0822530B1 (pt) * | 2008-04-03 | 2022-03-22 | Biosteed Gene Expression Tech. Co., Ltd | Método de preparação de um hormônio de crescimento humano glicolado por polietileno (modificado por peg), hormônio do crescimento humano modificado por peg de menor peso molecular aparente e seu uso, preparação de hormônio do crescimento humano modificado por peg de menor peso molecular aparente e seu método de preparação e composição |
| WO2011118739A1 (ja) | 2010-03-26 | 2011-09-29 | 協和発酵キリン株式会社 | 新規修飾部位導入抗体および抗体フラグメント |
| CN110591079B (zh) * | 2018-06-13 | 2022-08-02 | 厦门赛诺邦格生物科技股份有限公司 | 单官能化非线性聚乙二醇的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4157384A (en) * | 1972-01-28 | 1979-06-05 | Wilkinson Sword Limited | Compositions having a physiological cooling effect |
| US4855075A (en) * | 1988-03-14 | 1989-08-08 | Sandoz Ltd. | Ethoxylates of alkyl and alkenyl catechols |
| JP2997004B2 (ja) | 1989-05-26 | 2000-01-11 | 住友製薬株式会社 | ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法 |
| JPH04218000A (ja) * | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
| JP3051145B2 (ja) * | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
| US5229366A (en) * | 1990-10-23 | 1993-07-20 | Fuji Photo Film Co., Ltd. | Peptide-containing polyethylene glycol derivatives and application thereof |
| US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5730990A (en) * | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
| CA2204726A1 (en) * | 1994-11-09 | 1996-12-27 | Robin E. Offord | Functionalized polymers for site-specific attachment |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| IT1277596B1 (it) | 1995-09-15 | 1997-11-11 | Bracco Spa | Composti macromolecolari di tipo dendrimerico |
| DE19640092A1 (de) * | 1996-09-28 | 1998-04-16 | Beiersdorf Ag | Strukturen mit Lipid-Doppelmembranen, in deren lipophilen Bereich längerkettige Moleküle eintauchen oder durch hydrophobe Wechselwirkungen an solche Moleküle angedockt sind |
| AU762621B2 (en) | 1998-04-28 | 2003-07-03 | Merck Serono Sa | Polyol-IFN-beta conjugates |
-
2000
- 2000-12-22 AT AT00985846T patent/ATE522563T1/de not_active IP Right Cessation
- 2000-12-22 JP JP2001548589A patent/JP4593048B2/ja not_active Expired - Fee Related
- 2000-12-22 CA CA2395254A patent/CA2395254C/en not_active Expired - Fee Related
- 2000-12-22 EP EP00985846A patent/EP1270642B1/de not_active Expired - Lifetime
- 2000-12-22 US US10/168,956 patent/US7691367B2/en not_active Expired - Fee Related
- 2000-12-22 WO PCT/JP2000/009159 patent/WO2001048052A1/ja not_active Ceased
- 2000-12-22 AU AU22234/01A patent/AU2223401A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2223401A (en) | 2001-07-09 |
| EP1270642B1 (de) | 2011-08-31 |
| EP1270642A4 (de) | 2006-01-18 |
| EP1270642A1 (de) | 2003-01-02 |
| WO2001048052A1 (en) | 2001-07-05 |
| US20030219404A1 (en) | 2003-11-27 |
| JP4593048B2 (ja) | 2010-12-08 |
| CA2395254A1 (en) | 2001-07-05 |
| US7691367B2 (en) | 2010-04-06 |
| CA2395254C (en) | 2010-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE522563T1 (de) | Verzweigte polyalkylenglykole | |
| DE60236796D1 (de) | Verzweigte polyalkylenglykole | |
| NZ517012A (en) | Peptides that lower blood glucose levels | |
| DE112006000677A5 (de) | Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form | |
| EP2298331A3 (de) | Verwendung von Transthyretinpeptid-/-proteinfusionen zur Erhöhung der Serumshalbwertszeit von pharmakologisch aktiven Peptiden/Proteinen | |
| GB0121591D0 (en) | Hybrid and tandem expression of neisserial proteins | |
| CA2380569A1 (en) | Chimeric polypeptides, method for production and uses thereof | |
| EA200901108A1 (ru) | Соагонисты глюкагоновых/glp-1-рецепторов | |
| PT2241575E (pt) | Polipéptidos de fusão que contêm o igf-1 e utilizações terapêuticas desses polipéptidos | |
| DE69735580D1 (de) | An aminosaeure angereicherte speicherproteine, insbesondere an lysin angereicherte mais-gamma-zeine, und diese exprimierende pflanzen | |
| IL127583A0 (en) | Method for the production of polypeptides | |
| ATE322503T1 (de) | Gefrierschutzprotein | |
| FI961044A0 (fi) | Kininogeeni-inhibiittorit | |
| DE602004028266D1 (de) | Angiogene peptide und ihre verwendungen | |
| DE60138703D1 (de) | Transportpeptide abgeleitet von erns protein | |
| DK0383599T3 (da) | Protein-anticancermiddel | |
| TW200505943A (en) | Polypeptide | |
| WO1999061468A3 (en) | The induction of antibiotic peptides by lait (scd14) protein | |
| NO20005081D0 (no) | Et polypeptid inneholdende aminosyren fra et N-terminalt kolinbindende protein A-truncat, vaksine avledet derfra og anvendelser derav | |
| MXPA05008785A (es) | Esteres de polietilen glicol activados. | |
| AR018045A1 (es) | Proteina placentaria 13 y polipetido, molecula de adn que los codifica, anticuerpos capaces de enlazarse a ellos, metodo para la deteccion decomplicaciones relacionadas con el embarazo, metodo recombinante para la produccion de dicha proteina y un equipo para el diagnostico de complicacionesrelacion | |
| AR026068A1 (es) | Peptidos modificados y peptidomimeticos para el uso en inmunoterapia. | |
| EA200001252A1 (ru) | КОМПОЗИЦИЯ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА-β-1A(IFN-β-1A) ЧЕЛОВЕКА | |
| RU98109238A (ru) | Пептиды с контринсулярным действием | |
| KR890701628A (ko) | 단백질(성) 감미제의 제조 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |